Bottom line
CNRZX vs RIDEX: the short answer
CNRZX (City National Rochdale Fixed Income Opportunities Fund) and RIDEX (Income Fund Of America) are both mutual funds.
But RIDEX is far broader, holding 3,344 positions to 942 for CNRZX, so beyond the top names it adds exposure CNRZX doesn't have.
RIDEX is cheaper at 0.61% vs 0.96% — a difference of $35 a year per $10,000 invested.
Over five years, RIDEX returned +9.0% a year vs +3.4% for CNRZX.
Updated Nov 19, 2026
CNRZX vs RIDEX side by side
| CNRZX | RIDEX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | City National Rochdale | American Funds (Capital Group) |
| Category | Core / Intermediate Bond | Core / Intermediate Bond |
| Expense ratio | 0.96% | 0.61% |
| Annual cost per $10k | $96 | $61 |
| 10-yr cost on $10k (prospectus) | $1,178 | $762 |
| Max front load | — | 0% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +8.1% | +17.7% |
| 5-yr return (annualized) | +3.4% | +9.0% |
| 10-yr return (annualized) | +4.3% | +8.6% |
| Best quarter | — | +10.3% |
| Worst quarter | — | −16.2% |
| Net assets (fund) | $1.5B | $148.3B |
| Number of holdings | 942 | 3,344 |
| Portfolio turnover | 4% | 77% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Holdings overlap
CNRZX and RIDEX share none of their top holdings.
CNRZX top 10
- N/a — 5.55%
- N/a — 4.89%
- N/a — 2.71%
- United States of America — 2.36%
- United States of America — 2.02%
- Armada Euro Clo Designated Activity Company — 1.06%
- N/a — 1.06%
- N/a — 1.04%
- N/a — 0.83%
- N/a — 0.82%
RIDEX top 10
- Capital Group Central Cash Fund — 4.88%
- Philip Morris International Inc — 2.39%
- Amgen Inc — 2.02%
- Eog Resources Inc — 1.85%
- Cvs Health Corp — 1.67%
- Unitedhealth Group Inc — 1.57%
- Abbvie Inc — 1.45%
- Gilead Sciences Inc — 1.36%
- Southern Co/the — 1.30%
- Canadian Natural Resources Ltd — 1.29%
FAQ
What is the difference between CNRZX and RIDEX?
Which is cheaper, CNRZX or RIDEX?
Should I own both CNRZX and RIDEX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.